Nintx (Next Innovative Therapeutics), a biotech company focused on developing treatments for multifactorial diseases using Brazil’s biodiversity, has raised an additional US$ 10 million following a US$ 3 million seed investment in 2022. The funds will support the company’s R&D of eight new drug programs, partnerships with companies like Adeste and Centroflora, and research institutions such as CIEnP and CNPEM. Nintx utilizes proprietary technologies, including xGIbiomics® to simulate the gastrointestinal system and GAIApath®, a data analytics platform mapping connections between plants, natural products, biological targets, the human microbiome, and multifactorial diseases.
The company’s business model involves advancing therapies through preclinical studies and licensing them to pharmaceutical companies for clinical development. Nintx expects to license its first drug candidate within three years. Investors in the Series A round include Pitanga, Ecoa Capital, MOV Investimentos, and strategic partners Tiaraju and Adeste. Additionally, the company received a US$ 2.5 million grant from FINEP, a public entity promoting innovation.
Nintx’s leadership restructuring aligns with its growth plans. Stephani Saverio, previously Global Vice President of Business Development at Knight Therapeutics, will become CEO in January 2025. This leadership shift marks a pivotal moment for Nintx as they aim to pioneer innovative therapies and establish themselves in the global biotech market. With a focus on social and environmental impact, the company supports agroforestry practices, small farmers, and knowledge-sharing agreements with local communities. This holistic approach to business and biotechnology sets Nintx apart in Brazil’s pharmaceutical sector, positioning them for international competitiveness.
